Alzheimer’s disease (AD) is associated with increased production of new neurons (neurogenesis), which may be directed at brain repair. However, the effect of drugs used to treat AD on neurogenesis is unknown. We administered tacrine, galantamine or memantine to mouse cerebral cortical cultures in vitro, and to mice in vivo, and measured neurogenesis by labeling newborn cells with bromodeoxyuridine (BrdU) and confirming their neuronal lineage by celltypespecific protein expression. All three drugs increased BrdU incorporation into cortical cultures in vitro by up to 40, and increased BrdU labeling of cells in neuroproliferative regions of the adult mouse brain in vivo by 2645. BrdU labeling was associated with neuronal markers, such as Hu and betaIII tubulin. Thus, drugs used to treat AD increase cerebral neurogenesis both in vitro and in vivo, which may contribute to their therapeutic effects.
October 23, 2020
In this panel discussion from Ending Age-Related Diseases 2020, Vadim Gladyshev of Harvard Medical School chairs a panel with Steve Horvath of UCLA, […]
October 22, 2020
A new analysis has revealed a core set of genes involved in aging in both humans and mice. Together with a broader set of age-related genes assembled by the study , this resource will serve as […]
October 20, 2020
An international collective of scientists has discovered a new cellular process: telomere transfer from antigen-presenting cells to T cells that boosts the latter’s lifespan and proliferative […]
October 19, 2020
Researchers have successfully used the CRISPR/Cas9 gene editing tool to destroy Ewing’s sarcoma and chronic myeloid leukemia tumor cells by targeting the fusion genes responsible […]
October 16, 2020
In his presentation at Ending Age-Related Diseases 2020, LEAF board member Javier Noris discussed the Longevity Impact Fund, the reasons why biotechnology funding has been lacking, the "valley of death" that must be crossed in order to fully fund early-stage research through the clinical trial process, and new ways in which venture capital can fund...
October 16, 2020
Insilico Medicine has announced a historic deal with the Taisho Pharmaceutical Company, which is based in Japan, in a partnership to identify and develop new senolytic drugs. The companies have agreed to collaborate on AI-powered […]